Table 1.
Baseline patient characteristics, laboratory data, and CT quantitative measures of body composition.
| All patients (n = 69) | |
|---|---|
| Patient characteristics: Demographics | |
| Age (year) | 65 ± 11.4 (43–88) |
| BMI (kg/m2) | 24.9 ± 6.1 (16.9–52.8) |
| BMI range* | |
| Underweight (<18.5) | 5 (7.69) |
| Normal (18.5–22.9) | 23 (35.38) |
| Overweight (23.0–24.9) | 8 (12.31) |
| Obesity (≥25.0) | 29 (44.62) |
| FIGO stage | |
| IB | 1 (1%) |
| IIA | 1 (1%) |
| IIB | 2 (3%) |
| IIIA | 2 (3%) |
| IIIB | 5 (7%) |
| IIIC | 38 (55%) |
| IV | 20 (29%) |
| Patient characteristics: Chemotherapy | |
| NACT no. of patients | 25 (36%) |
| Dose reduction, no. of patients | 25 (36%) |
| Early discontinuation of chemotherapy | 9 (13%) |
| Cycle delays (≥ 2 weeks) | 8 (12%) |
| Laboratory Tests | |
| Lactate dehydrogenase (102 U/L) | 551.84 ± 355.14 (266–1,727) |
| Albumin (g/L) | 34.90 ± 7.70 (14–46) |
| Hemoglobin (102 g/L) | 120.79 ± 18.15 (74–163) |
| White blood cell count (109/L) | 7.27 ± 3.39 (1.6–19.3) |
| Lymphocyte count (109/L) | 1.41 ± 0.52 (0.26–2.87) |
| Body Composition Parameters | |
| SAT (×102) (cm2) | 2.12 ± 1.27 (0.23-6.90) |
| VAT (×102) (cm2) | 0.68 ± 0.60 (0–0.233) |
| SMA (×102) (cm2) | 1.19 ± 0.26 (0.71–2.24) |
| Mean SMD (×102) (HU) | 0.28 ± 0.16 (-0.18–0.56) |
| SMI (×102) (SMA/height2) | 0.47 ± 0.10 (0.26–0.81) |
| Chemotherapy toxicity in sarcopenic patients | |
| Sarcopenia** | 20 (29%) |
| Dose reduction | 8 (40%) |
| Early discontinuation of chemotherapy | 3 (15%) |
| Cycle delays | 2 (10%) |
Quantitative data reported as mean ± standard deviation (minimum-maximum).
BMI, body mass index; FIGO, International Federation of Gynaecology and Obstetrics; NACT, neoadjuvant chemotherapy; SAT, subcutaneous adipose tissue; VAT, visceral adipose tissue; SMA, skeletal muscle area; SMD, skeletal muscle density; SMI, skeletal muscle index. *Missing values: BMI Range (n = 65).
**Optimal cutoff values determined by Martin (2013) (SMI < 41).